Examkin

Question

Difficulty: HardStatistical Inference and Hypothesis Testing

A consortium of cardiovascular researchers conducts a large-scale clinical trial comparing a novel subcutaneous PCSK9 inhibitor to standard high-intensity oral statin therapy for the secondary prevention of major adverse cardiovascular events (MACE). The trial enrolls 45,000 adults with documented coronary artery disease. Patients are randomly assigned to receive either the novel inhibitor or the oral statin and are followed for five years.

At the conclusion of the study, the incidence of MACE is 9.1% in the novel inhibitor group and 9.4% in the statin group. The relative risk (RR) for MACE is calculated to be 0.97 (95% CI: 0.95 - 0.99, p=0.02p = 0.02). Based on these findings, the pharmaceutical sponsor petitions to have the new drug listed as the preferred first-line agent, citing its definitive statistical superiority over standard therapy.

Which of the following is the most scientifically sound critique of this petition?

  1. The study's extremely large sample size generated high statistical power, leading to a statistically significant result for a risk reduction that lacks clinical significance.Answer
  2. B
    The trial's structure of assigning exposures and following forward for outcomes represents a case-control design, which cannot establish definitive causality.
  3. C
    The narrow 95% confidence interval demonstrates that effect modification is present, meaning the drug's efficacy depends heavily on unmeasured patient characteristics.
  4. D
    The positive predictive value of the medication's efficacy will mathematically decrease if implemented in populations with a lower prevalence of heart disease.
  5. E
    The p-value of 0.02 suggests that residual confounding was not adequately addressed by the randomization process, invalidating the relative risk.

Answer

The study possesses excessive statistical power due to its massive sample size, detecting an absolute risk reduction (0.3%) that is statistically significant but clinically insignificant.
This scenario illustrates the critical divergence between statistical significance and clinical significance. The study enrolled 45,000 patients, providing enormous statistical power. Because statistical power (the ability to reject the null hypothesis when a true difference exists) directly increases with sample size, very large trials can detect minuscule differences between groups. Here, the absolute risk reduction (ARR) is only 0.3% (9.4% - 9.1%). This means approximately 333 patients would need to be treated (Number Needed to Treat = 1 / 0.003) with the novel agent for five years to prevent a single MACE. While the relative risk (0.97) and p-value (0.02) confirm the results are statistically significant (unlikely due to chance), the tiny magnitude of the benefit is not clinically meaningful enough to justify replacing standard therapy as a first-line agent.

Step-by-Step Solution

1
Analyze the statistical findings provided in the stem.
The relative risk is 0.97 with a 95% CI of 0.95 to 0.99 and a p-value of 0.02.
To verify that the outcome achieved statistical significance (p < 0.05 and CI does not cross 1.0).
2
Calculate the Absolute Risk Reduction (ARR) to assess the actual clinical impact.
ARR = 9.4% (statin group) - 9.1% (novel inhibitor group) = 0.3%.
Relative risk can exaggerate small absolute differences; ARR provides a better measure of the drug's actual clinical utility in the patient population.
3
Synthesize the statistical significance with the clinical magnitude in the context of the study design.
The 0.3% ARR is clinically negligible, but it achieved statistical significance (p<0.05p < 0.05) solely because the massive sample size (n=45,000n=45,000) provided enormous statistical power.
Large sample sizes can detect tiny, clinically irrelevant differences as statistically significant.

Key Concept

Clinical vs. Statistical Significance in Highly Powered Trials
Estimated Time:1m 30s
Rate this question

Topics

Statistical Inference and Hypothesis Testing

More questions from this topic